Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Total Liabilities
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has total liabilities worth $11.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Contineum Therapeutics, Inc. Class A Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Contineum Therapeutics, Inc. Class A Com (CTNM) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
China | CN¥1.23 Billion |
|
Shenzhen TVT Digital Technology Co Ltd
SHE:002835
|
China | CN¥319.14 Million |
|
Star Gas Partners LP
NYSE:SGU
|
USA | $624.38 Million |
|
Samse SA
PA:SAMS
|
France | €1.06 Billion |
|
Development Investment Construction JSC
VN:DIG
|
Vietnam | ₫7.57 Trillion |
|
Cub Elecparts Inc
TW:2231
|
Taiwan | NT$6.31 Billion |
|
Hana Tour
KO:039130
|
Korea | ₩511.44 Billion |
|
Metrics Income Opportunities Trust
AU:MOT
|
Australia | AU$5.06 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTNM market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 38.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Contineum Therapeutics, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total liabilities of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.65 Million | +5.90% |
| 2024-12-31 | $14.78 Million | -92.55% |
| 2023-12-31 | $198.32 Million | +1644.87% |
| 2022-12-31 | $11.37 Million | +27.28% |
| 2021-12-31 | $8.93 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more